Evidence map›Paper›PMID 21511322›Full record

ArticleVirology2011

Failure to activate the IFN-β promoter by a paramyxovirus lacking an interferon antagonist.

M J Killip, D F Young, C S Ross, S Chen, S Goodbourn, R E Randall

Open access · hybridAbstract read
In one paragraph

Article in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Single-cell analysis of early antiviral gene expression reveals a determinant of stochastic IFNB1 expression.Integrative biology : quantitative biosciences from nano to macro · 2017
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

M J KillipSchool of Biology, Centre for Biomolecular Sciences, North Haugh, University of St. Andrews, St. Andrews, Fife, UK.
D F Young
C S Ross
S Chen
S Goodbourn
R E Randall
University of St Andrews · GBSt George's, University of London · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

It is generally thought that pathogen-associated molecular patterns (PAMPs) responsible for triggering interferon (IFN) induction are produced during virus replication and, to limit the activation of the IFN response by these PAMPs, viruses encode antagonists of IFN induction. Here we have studied the induction of IFN by parainfluenza virus type 5 (PIV5) at the single-cell level, using a cell line expressing GFP under the control of the IFN-β promoter. We demonstrate that a recombinant PIV5 (termed PIV5-VΔC) that lacks a functional V protein (the viral IFN antagonist) does not activate the IFN-β promoter in the majority of infected cells. We conclude that viral PAMPs capable of activating the IFN induction cascade are not produced or exposed during the normal replication cycle of PIV5, and suggest instead that defective viruses are primarily responsible for inducing IFN during PIV5 infection in this system.

Indexed as

Promoter Regions, GeneticAnimalsCell LineChlorocebus aethiopsDefective VirusesFluorescent Antibody TechniqueGene Expression RegulationGreen Fluorescent ProteinsHumansImmunoblottingInterferon-betaMutationRubulavirusVero CellsViral ProteinsVirus ReplicationGreen Fluorescent ProteinsInterferon-betaViral ProteinsV protein, Paramyxovirus

Identifiers

PMID21511322
PMCPMC3107429
OpenAlexW2151948198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.